Manus secures £2.6m to support the commercialisation of NeuroMotor PenTM
Edinburgh, UK – 25 May 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has closed a £2.6m funding round to support the commercialisation of its innovative NeuroMotor PenTM – a medical device to aid diagnosis and monitoring of neuromotor … Read more
Agreement signed with Medispa to integrate NeuroMotor PenTM into Prevention Suite
Prevention Suite platform used by more than 10,000 pharmacies in Italy, Spain and Portugal. Partnership to be showcased at the annual Cosmofarma Exhibition in Bologna, Italy this weekend Edinburgh, UK – 5 May 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces … Read more
Agreement with Johnson & Johnson to use Neuromotor PenTM to detect neuromotor ad-verse effects following CAR T-cell therapy
Manus named awardee in ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire Challenge Edinburgh, UK – 24 April 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been named an awardee in the ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire … Read more
Manus joins ABHI US Accelerator 2022 cohort
12-month programme allows Manus to utilise ABHI’s expertise and connections within the US to strengthen strategy and de-risk market entry Edinburgh, UK – 22 February 2022: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announced that it has joined the Association of British … Read more
Appointment of Non-Executive Director and additional key hires
Appointment of Dr Guy Wood-Gush to the Board of Directors, and hires of Senior Data Scientist and Technical Operations and Project Manager Edinburgh, UK – 21 December 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Dr Guy Wood-Gush … Read more
FDA grants Breakthrough Device Designation for the Manus NeuroMotor Pen™
Designation provides priority regulatory review of the Manus NeuroMotor Pen™ designed to aid the diagnoses of Parkinson’s Disease Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been granted Breakthrough Designation by the U.S. Food and Drug Administration (“FDA”) for … Read more
Revolutionary non-invasive technology supporting early diagnosis of Parkinson’s disease showcased at MEDICA 2021
Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The … Read more
Novel digital biomarkers to aid in the diagnosis and tracking of symptoms in patients with Parkinson’s Disease
Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM Parkinson’s disease (PD) is a progressive neurological condition associated with dysfunction of the extrapyramidal system. The cardinal symptoms of PD are bradykinesia … Read more
ISO Certification of Quality Management System
Validates Manus as a medical device company allowing the Company to fully engage in commercial activities Edinburgh, UK – 17 June 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has received ISO 13485:2016 certification following an assessment of its … Read more
£600k grant funding from Innovate UK To validate the NeuroMotor PenTM for screening of dementias and cognitive im-pairment
Edinburgh, UK – 20 April 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, has received £600,000 grant funding from Innovate UK, to optimise and validate the NeuroMotor PenTM (NMP) for screening of dementias and cognitive impairment, over a two-year project. Only around … Read more